SEC Form 10-K filed by Dogwood Therapeutics Inc.
$DWTX
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
ATLANTA, April 11, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders, today announced that it has received written confirmation from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million. DWTX Chairman and CEO Greg Duncan stated, "We are pleased that the Company successfully implemented a plan to regain compliance and meet the equity requirement and is continuing to execute that plan going forward." He continued, "The Company has a strong cash positi
ATLANTA, April 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders today announced it believes it has regained compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1). DWTX Chairman and CEO Greg Duncan stated, "We appreciate the consideration Nasdaq has shown Dogwood Therapeutics, Inc." He continued, "The Company has a strong cash position of $17.5 million as of the end of Q1, with no debt, better positioning the Company to advance its continued mission to build shareholder value
-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain ("CINP") Phase 2b Trial - - Halneuron® CINP P2b study interim data readout is expected in Q4 2025 - - Conversion of existing $19.5M in debt to equity, strengthens balance sheet moving forward - - Capital raise provides operational runway through Q1 2026 - ATLANTA, March 31, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the fourth quarter and full year ended December 31, 2024. "We have made
3 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)
4 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)
3 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)
8-K - Dogwood Therapeutics, Inc. (0001818844) (Filer)
10-K - Dogwood Therapeutics, Inc. (0001818844) (Filer)
8-K - Dogwood Therapeutics, Inc. (0001818844) (Filer)
-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain ("CINP") Phase 2b Trial - - Halneuron® CINP P2b study interim data readout is expected in Q4 2025 - - Conversion of existing $19.5M in debt to equity, strengthens balance sheet moving forward - - Capital raise provides operational runway through Q1 2026 - ATLANTA, March 31, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the fourth quarter and full year ended December 31, 2024. "We have made
ATLANTA, March 12, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a development-stage biopharmaceutical company focused on advancing first-in-class, non-opioid, treatments for chronic and acute pain, announces that its largest shareholder, CK Life Sciences Int'l., (Holdings), Inc. ("CKLS") has agreed, through its wholly-owned subsidiary, Conjoint Inc. ("Conjoint"), to assign to the Company all outstanding indebtedness under the previously existing $19.5 million Loan Agreement plus accrued interest in exchange for 284.2638 shares of preferred equity of the Company, effective today. "We believe the decision by CKLS to exchange the outst
ATLANTA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced today that it will report third quarter 2024 financial results on Thursday, November 7, 2024 before the open of the financial markets. Management will also host a webcast and conference call on November 7, 2024 at 8:30 a.m. ET to discuss the results and provide a corporate update. The live and archived webcast of the call may be accessed on the Dogwood Therapeutics website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-506-0062 (domestic) or 973-5